within Pharmacolibrary.Drugs.ATC.L;

model L02BA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 1.7333333333333336e-05,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0032833333333333334,
    Tlag           = 600,            
    Vdp             = 0.112,
    k12             = 2.3,
    k21             = 2.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02BA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tamoxifen is a selective estrogen receptor modulator (SERM) widely used in the treatment and prevention of breast cancer, particularly hormone receptor-positive breast cancer. It remains a standard of care for pre-menopausal and post-menopausal women and is approved and in clinical use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy female volunteers, assessed after a single oral dose.</p><h4>References</h4><ol><li><p>Mueller-Schoell, A, et al., &amp; Kloft, C (2021). Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European journal of clinical pharmacology</i> 77(4) 441–464. DOI:<a href=\"https://doi.org/10.1007/s00228-020-03014-8\">10.1007/s00228-020-03014-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33165648/\">https://pubmed.ncbi.nlm.nih.gov/33165648</a></p></li><li><p>Sanchez-Spitman, AB, et al., &amp; Guchelaar, HJ (2019). Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. <i>Expert review of clinical pharmacology</i> 12(6) 523–536. DOI:<a href=\"https://doi.org/10.1080/17512433.2019.1610390\">10.1080/17512433.2019.1610390</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31008668/\">https://pubmed.ncbi.nlm.nih.gov/31008668</a></p></li><li><p>Buchanan, CM, et al., &amp; Wempe, MF (2007). Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta-cyclodextrin formulations. <i>Journal of pharmaceutical sciences</i> 96(3) 644–660. DOI:<a href=\"https://doi.org/10.1002/jps.20709\">10.1002/jps.20709</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17083091/\">https://pubmed.ncbi.nlm.nih.gov/17083091</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02BA01;
